(INDV) Indivior Ordinary Shares - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 4.436m USD | Total Return: 190.3% in 12m
Avg Turnover: 72.8M
Qual. Beats: 0
Rev. Trend: 93.0%
Qual. Beats: 6
Warnings
Altman Z'' 0.65 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Idiosyncratic Leader, Confidence
Indivior PLC (INDV) is a pharmaceutical company specialized in developing and commercializing buprenorphine-based treatments for opioid use disorder (OUD). Its primary revenue drivers include SUBLOCADE, an extended-release injectable, and SUBOXONE, which is available in film and tablet formats. The company operates globally across North America, Europe, and Australia, maintaining a clinical pipeline focused on long-acting injectables and selective orexin-1 receptor antagonists.
The company operates within the biotechnology sector, where business models often rely on patent protection and high barriers to entry due to stringent regulatory approval processes. Indivior’s focus on the OUD market addresses a significant public health demand, utilizing a specialized sales force to navigate complex healthcare reimbursement systems and clinical provider networks.
Investors can further evaluate these fundamentals and market positioning by reviewing the comprehensive data available on ValueRay.
- Sublocade prescription growth remains primary driver of long-term revenue and market share
- Suboxone generic competition and litigation settlements impact cash flow and margins
- Expansion of opioid use disorder treatment access increases total addressable market
- Clinical trial results for INDV-2000 determine future pipeline valuation and diversification
- Government healthcare spending and reimbursement policies dictate patient access and pricing
| Net Income: 251.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA -24.97 > 1.0 |
| NWC/Revenue: -8.68% < 20% (prev -10.42%; Δ 1.74% < -1%) |
| CFO/TA -0.09 > 3% & CFO -103.0m > Net Income 251.0m |
| Net Debt (357.0m) to EBITDA (452.0m): 0.79 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (129.0m) vs 12m ago 4.30% < -2% |
| Gross Margin: 83.11% > 18% (prev 0.82%; Δ 8.23k% > 0.5%) |
| Asset Turnover: 100.4% > 50% (prev 85.16%; Δ 15.23% > 0%) |
| Interest Coverage Ratio: 10.88 > 6 (EBITDA TTM 452.0m / Interest Expense TTM 40.0m) |
| A: -0.09 (Total Current Assets 667.0m - Total Current Liabilities 779.0m) / Total Assets 1.20b |
| B: -0.23 (Retained Earnings -280.0m / Total Assets 1.20b) |
| C: 0.34 (EBIT TTM 435.0m / Avg Total Assets 1.29b) |
| D: -0.23 (Book Value of Equity -309.0m / Total Liabilities 1.34b) |
| Altman-Z'' = 0.65 = B |
| DSRI: 1.06 (Receivables 285.0m/243.0m, Revenue 1.29b/1.17b) |
| GMI: 0.98 (GM 83.11% / 81.64%) |
| AQI: 1.15 (AQ_t 0.29 / AQ_t-1 0.26) |
| SGI: 1.10 (Revenue 1.29b / 1.17b) |
| TATA: 0.30 (NI 251.0m - CFO -103.0m) / TA 1.20b) |
| Beneish M = -2.52 (Cap -4..+1) = A |
As of May 30, 2026, the stock is trading at USD 36.02 with a total of 1,608,105 shares traded.
Over the past week, the price has changed by -3.84%,
over one month by +5.48%,
over three months by +10.09% and
over the past year by +190.25%.
Indivior Ordinary Shares has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy INDV.
- StrongBuy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.5 | 43% |
P/E Trailing = 19.2462
P/E Forward = 12.2549
P/S = 3.4389
P/B = 145.2492
Revenue TTM = 1.29b USD
EBIT TTM = 435.0m USD
EBITDA TTM = 452.0m USD
Long Term Debt = 486.0m USD (from longTermDebt, last quarter)
Short Term Debt = 9.00m USD (from shortTermDebt, last quarter)
Debt = 532.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 23.0m
Net Debt = 357.0m USD (calculated: Debt 532.0m - CCE 175.0m)
Enterprise Value = 4.79b USD (4.44b + Debt 532.0m - CCE 175.0m)
Interest Coverage Ratio = 10.88 (Ebit TTM 435.0m / Interest Expense TTM 40.0m)
EV/FCF = -25.96x (Enterprise Value 4.79b / FCF TTM -184.6m)
FCF Yield = -3.85% (FCF TTM -184.6m / Enterprise Value 4.79b)
FCF Margin = -14.30% (FCF TTM -184.6m / Revenue TTM 1.29b)
Net Margin = 19.44% (Net Income TTM 251.0m / Revenue TTM 1.29b)
Gross Margin = 83.11% ((Revenue TTM 1.29b - Cost of Revenue TTM 218.0m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 82.12%)
Tobins Q-Ratio = 4.00 (Enterprise Value 4.79b / Total Assets 1.20b)
Interest Expense / Debt = 7.52% (Interest Expense 40.0m / Debt 532.0m)
Taxrate = 22.61% (26.0m / 115.0m)
NOPAT = 336.7m (EBIT 435.0m * (1 - 22.61%))
Current Ratio = 0.86 (Total Current Assets 667.0m / Total Current Liabilities 779.0m)
Debt / Equity = -3.69 (negative equity) (Debt 532.0m / totalStockholderEquity, last quarter -144.0m)
Debt / EBITDA = 0.79 (Net Debt 357.0m / EBITDA 452.0m)
Debt / FCF = -1.93 (negative FCF - burning cash) (Net Debt 357.0m / FCF TTM -184.6m)
Total Stockholder Equity = -176.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.52% (Net Income 251.0m / Total Assets 1.20b)
RoE = 243.1% (Net Income TTM 251.0m / Total Stockholder Equity 103.2m)
RoCE = 73.82% (EBIT 435.0m / Capital Employed (Equity 103.2m + L.T.Debt 486.0m))
RoIC = 78.88% (NOPAT 336.7m / Invested Capital 426.8m)
WACC = 7.21% (E(4.44b)/V(4.97b) * Re(7.38%) + D(532.0m)/V(4.97b) * Rd(7.52%) * (1-Tc(0.23)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -59.81 | Cagr: -2.64%
[DCF] Fair Price = unknown (Cash Flow -184.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.61 | # QB: 0
Revenue Correlation: 93.04 | Revenue CAGR: 7.50% | SUE: 1.77 | # QB: 6
EPS current Quarter (2026-06-30): EPS=0.92 | Chg30d=+22.67% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.99 | Chg30d=+21.32% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=3.85 | Chg30d=+23.08% | Revisions=+50% | GrowthEPS=+54.1% | GrowthRev=+1.5%
EPS next Year (2027-12-31): EPS=3.92 | Chg30d=+13.44% | Revisions=+50% | GrowthEPS=+1.8% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +50%